2024 voluntary scheme for branded medicines pricing, access and growth
An agreement between DHSC, NHS England and ABPI to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector.
- From:
- Department of Health and Social Care
- Published
- 14 December 2023
- Last updated
- 2 June 2026 — See all updates
Documents
2024 voluntary scheme for branded medicines pricing, access and growth
PDF, 1.451.17 MB, 97 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Annexes to the 2024 voluntary scheme for branded medicines pricing, access and growth
PDF, 825937 KB, 7981 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
The 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) is a voluntary agreement between the Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI).
The voluntary scheme aims to:
- promote better patient outcomes and a healthier population
- support UK economic growth
- contribute to a financially sustainable NHS
The voluntary scheme willcame come into force on 1 January 2024 and will beremain in place for 5 years until 31 December 2028.
Updates to this page
Published 14 December 2023
Last updated 2 June 2026
href="#full-history">+ show all updates
-
All documents have been updated following the implementation of the US-UK partnership on pharmaceuticals. Changes reflect the new NICE cost-effectiveness threshold, a new 15% ceiling on VPAG headline payment percentages for the remaining years of the scheme, and a commitment to ensuring VPAG does not recoup any estimated increase in spending on branded medicines due to the arrangement.
-
First published.
Sign up for emails or print this page
Update history
2026-06-02 09:56
All documents have been updated following the implementation of the US-UK partnership on pharmaceuticals. Changes reflect the new NICE cost-effectiveness threshold, a new 15% ceiling on VPAG headline payment percentages for the remaining years of the scheme, and a commitment to ensuring VPAG does not recoup any estimated increase in spending on branded medicines due to the arrangement.
2023-12-14 18:37
First published.
2024 voluntary scheme for branded medicines pricing, access and growth
PDF, 1.451.17 MB, 97 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Annexes to the 2024 voluntary scheme for branded medicines pricing, access and growth
PDF, 825937 KB, 7981 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
The 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) is a voluntary agreement between the Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI).
The voluntary scheme aims to:
- promote better patient outcomes and a healthier population
- support UK economic growth
- contribute to a financially sustainable NHS
The voluntary scheme willcame come into force on 1 January 2024 and will beremain in place for 5 years until 31 December 2028.
Updates to this page
Published 14 December 2023
Last updated 2 June 2026
href="#full-history">+ show all updates
-
All documents have been updated following the implementation of the US-UK partnership on pharmaceuticals. Changes reflect the new NICE cost-effectiveness threshold, a new 15% ceiling on VPAG headline payment percentages for the remaining years of the scheme, and a commitment to ensuring VPAG does not recoup any estimated increase in spending on branded medicines due to the arrangement.
-
First published.
Sign up for emails or print this page
Update history
2026-06-02 09:56
All documents have been updated following the implementation of the US-UK partnership on pharmaceuticals. Changes reflect the new NICE cost-effectiveness threshold, a new 15% ceiling on VPAG headline payment percentages for the remaining years of the scheme, and a commitment to ensuring VPAG does not recoup any estimated increase in spending on branded medicines due to the arrangement.
2023-12-14 18:37
First published.
Details
The 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) is a voluntary agreement between the Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI).
The voluntary scheme aims to:
- promote better patient outcomes and a healthier population
- support UK economic growth
- contribute to a financially sustainable NHS
The voluntary scheme willcame come into force on 1 January 2024 and will beremain in place for 5 years until 31 December 2028.
Updates to this page
-
All documents have been updated following the implementation of the US-UK partnership on pharmaceuticals. Changes reflect the new NICE cost-effectiveness threshold, a new 15% ceiling on VPAG headline payment percentages for the remaining years of the scheme, and a commitment to ensuring VPAG does not recoup any estimated increase in spending on branded medicines due to the arrangement.
-
First published.
Sign up for emails or print this page
Update history
2026-06-02 09:56
All documents have been updated following the implementation of the US-UK partnership on pharmaceuticals. Changes reflect the new NICE cost-effectiveness threshold, a new 15% ceiling on VPAG headline payment percentages for the remaining years of the scheme, and a commitment to ensuring VPAG does not recoup any estimated increase in spending on branded medicines due to the arrangement.
2023-12-14 18:37
First published.